GB1574302A - Stable sprayable anesthetic solution - Google Patents

Stable sprayable anesthetic solution Download PDF

Info

Publication number
GB1574302A
GB1574302A GB2407078A GB2407078A GB1574302A GB 1574302 A GB1574302 A GB 1574302A GB 2407078 A GB2407078 A GB 2407078A GB 2407078 A GB2407078 A GB 2407078A GB 1574302 A GB1574302 A GB 1574302A
Authority
GB
United Kingdom
Prior art keywords
percent
anesthetic
water
sodium sulfosuccinate
composition according
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired
Application number
GB2407078A
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Scherico Ltd
Original Assignee
Scherico Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Scherico Ltd filed Critical Scherico Ltd
Publication of GB1574302A publication Critical patent/GB1574302A/en
Expired legal-status Critical Current

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/10Dispersions; Emulsions
    • A61K9/12Aerosols; Foams

Description

(54) STABLE, SPRAYABLE ANESTHETIC SOLUTION (71) We, SCHERICO LTD., of Topferstrasse 5, Lucerne, Switzerland, a body corporate constituted under the laws of Switzerland, do hereby declare the invention for which we pray that a patent may be granted to us and the method by which it is to be performed, to be particularly described in and by the following statement: This invention relates to a stable, cosmetically elegant solution useful as a topical anesthetic when applied as a non-aerosol spray. It is relatively nonflammable and exhibits no microscopic crystallization. The preparation is designed for relief of surface pain and itching and provides soothing temporary relief of minor burns, cuts, scratches, sunburn and other minor skin irritations.
There are many caine-type pain relieving agents which are used in topical anesthetic compositions, the most common of which is benzocaine. Since many of these pain relieving agents are insoluble or only slightly soluble in water, solvents other than water have generally been used, such as propylene glycol as taught in U.S. Patent 2,628,182 and the polyethylene glycol esters taught in U.S. Patent 3,322,624. However, the resulting preparations were generally found to be unstable, particularly at low temperatures, with the pain-relieving agent crystallizing or settling out. The problem is particularly acute for topical anesthetic concentrations over 0.5%. This problem is especially serious in a spray device since the crystals can block the outlet orifice of the container and render the device inoperable.
Topical anesthetic compositions have traditionally been sold in the form of ointments lotions, creams, and aerosol and non-aerosol sprays. The sprays are particularly desirable since they are convenient and present no danger of contamination to the product. They provide a generally desirable cooling effect on sunburned skin and cause less irritation to sensitive skin than would be produced by the rubbing on of a lotion or like product.
However, the aerosols containing fluorocarbon propellants are undesirable for environmental reasons and the hydrocarbon propellants are highly flammable.
The non-aerosol spray compositions which contain water-insoluble caine-type anesthetics generally require a high concentration of solvent to dissolve the anesthetic. Unfortunately, a system which contains more than 35-40 percent of an alcohol solvent will tend to dry the skin and is potentially hazardous since it tends to be highly flammable. If the alcohol solvent concentration is decreased to a safe level, the formulation is subject to microscopic crystallization of the anesthetic and generally gives a poor spray pattern.
A stable, relatively nonflammable, cosmetically elegant, sprayable topical anesthetic formulation has now surprisingly been found. This formulation is an aqueous solution containing 0.2 - 2.5 percent of a water-insoluble topical caine-type anesthetic, such as benzocaine; 0.3 - 0.6 percent of di-(C5-C8) alkyl sodium sulfosuccinate; 20 - 35 percent of a cosmetically acceptable, water-miscible alcohol in which the caine-type anesthetic is soluble; 10 - 25 percent of a cosmetically acceptable, water-miscible glycol which is a liquid at 25"C and in which the cain-type anesthetic is soluble; the maximum concentration of said solvents being 47 percent; and at least 50 percent water.The resulting formulation is stable at low temperatures, does not excessively dry the skin, exhibits a good spray pattern, and does not exhibit the high flammability characteristically associated with high concentrations of flammable solvents.
The formulation can be used in any non-aerosol spray assembly. Many such spray assemblies are widely known and used, such as the squeeze spray assembly shown in U.S.
Patents 3,361,304 and 3,474,936, or the pump spray system shown in U.S. Patents 4,010,874 and 4,022,354. The spray assembly will generally comprise a reservoir for holding the sprayable composition; a means for mixing the composition with air; and a means to dispense the air/liquid mixture as a spray. This is usually accomplished by creating a pressure differential between the atmosphere and the inside of the container, e.g. a pumper or squeezing a resilient container wall.
For purposes of this specification, the term "caine-type" anesthetic is used to refer to those amino-substituted phenyl esters and amides distinguishable by having a generic name ending in the syllable "caine". (See U.S. Patent 3,624,224.) Benzocaine is the most common compound in this class to be used in topical anesthetic formulations. Other suitable water-insoluble caine-type anesthetics are lido-caine, dibucaine and tetracaine. At least 1 percent anesthetic is preferred in this product with the most preferred range being 1 2 percent.
There are several suitable di-(C5-C8) alkyl esters of sodium sulfosuccinate which are commercially available, such as dioctyl sodium sulfosuccinate, dihexyl sodium sulfosuccinate, and diamyl sodium sulfosuccinate. The preferred compound is dioctyl sodium sulfosuccinate in a concentration of 0.4 - 0.5 percent.
Suitable water-miscible alcohol solvents are isopropyl alcohol and ethyl alcohol. Suitable water-miscible glycol solvents are propylene glycol and polyethylene glycol having a molecular weight of 200 - 600. A preferred composition contains 35 - 45 percent of solvents and most preferably contains 20 - 25 percent of isopropyl alcohol and 15 - 20 percent of polyethylene glycol having a molecular weight of 200 - 600. When reference is made to the solubility of the anesthetic in either of the solvents, a solubility of at least 5 percent in the solvent at 25"C is meant.
The concentration of water is at least 50 percent with a preferred concentration of 50 - 60 percent.
Various optional ingredients may be included in the formulation such as perfumes; preservatives, e.g. parabens; antiseptics, e.g. triclosan, phenol; humectants; emollients; antioxidants; chelating agents, e.g. disodium EDTA; dyes; foaming agents; as well as any other class of material whose presence may be cosmetically or otherwise desirable. Phenol, which is primarily used for its antiseptic properties, has also surprisingly been found to improve the low temperature stability of these formulations in concentrations of 0.2 - 0.5 percent.
The following non-limiting example is presented to illustrate the invention. The terminology is in conformance to the CTFA Cosmetics Ingredient Dictionary, 1977 edition.
The percentages used throughout the specification and the claims are weight percents unless indicated otherwise.
Example A topical anesthetic solution is prepared according to the following formulation: Part A Weight (kg) Water 55.65 Isopropyl Alcohol 13.75 Disodium EDTA 0.05 Dioctyl Sodium Sulfosuccinate 0.45 Part B Isopropyl Alcohol 11.25 Polyethylene Glycol (M.W. 400) 16.40 Triclosan 0.10 Benzocaine 2.00 Phenol 90% Solution 0.35 100.00 kg The ingredients of Part A are agitated until all solids dissolve. The ingredients of Part B are agitated until a solution results. The mixture of Part B is then blended with the mixture of Part A. The pH of the resulting formulation is 6.5.
WHAT WE CLAIM IS: 1. A stable sprayable anesthetic solution comprising: 0.2 - 2.5 percent of a water-insoluble caine-type anesthetic; 0.3 - 0.6 percent of a di-(C5-CR) alkyl sodium sulfosuccinate;
**WARNING** end of DESC field may overlap start of CLMS **.

Claims (12)

**WARNING** start of CLMS field may overlap end of DESC **. Patents 3,361,304 and 3,474,936, or the pump spray system shown in U.S. Patents 4,010,874 and 4,022,354. The spray assembly will generally comprise a reservoir for holding the sprayable composition; a means for mixing the composition with air; and a means to dispense the air/liquid mixture as a spray. This is usually accomplished by creating a pressure differential between the atmosphere and the inside of the container, e.g. a pumper or squeezing a resilient container wall. For purposes of this specification, the term "caine-type" anesthetic is used to refer to those amino-substituted phenyl esters and amides distinguishable by having a generic name ending in the syllable "caine". (See U.S. Patent 3,624,224.) Benzocaine is the most common compound in this class to be used in topical anesthetic formulations. Other suitable water-insoluble caine-type anesthetics are lido-caine, dibucaine and tetracaine. At least 1 percent anesthetic is preferred in this product with the most preferred range being 1 2 percent. There are several suitable di-(C5-C8) alkyl esters of sodium sulfosuccinate which are commercially available, such as dioctyl sodium sulfosuccinate, dihexyl sodium sulfosuccinate, and diamyl sodium sulfosuccinate. The preferred compound is dioctyl sodium sulfosuccinate in a concentration of 0.4 - 0.5 percent. Suitable water-miscible alcohol solvents are isopropyl alcohol and ethyl alcohol. Suitable water-miscible glycol solvents are propylene glycol and polyethylene glycol having a molecular weight of 200 - 600. A preferred composition contains 35 - 45 percent of solvents and most preferably contains 20 - 25 percent of isopropyl alcohol and 15 - 20 percent of polyethylene glycol having a molecular weight of 200 - 600. When reference is made to the solubility of the anesthetic in either of the solvents, a solubility of at least 5 percent in the solvent at 25"C is meant. The concentration of water is at least 50 percent with a preferred concentration of 50 - 60 percent. Various optional ingredients may be included in the formulation such as perfumes; preservatives, e.g. parabens; antiseptics, e.g. triclosan, phenol; humectants; emollients; antioxidants; chelating agents, e.g. disodium EDTA; dyes; foaming agents; as well as any other class of material whose presence may be cosmetically or otherwise desirable. Phenol, which is primarily used for its antiseptic properties, has also surprisingly been found to improve the low temperature stability of these formulations in concentrations of 0.2 - 0.5 percent. The following non-limiting example is presented to illustrate the invention. The terminology is in conformance to the CTFA Cosmetics Ingredient Dictionary, 1977 edition. The percentages used throughout the specification and the claims are weight percents unless indicated otherwise. Example A topical anesthetic solution is prepared according to the following formulation: Part A Weight (kg) Water 55.65 Isopropyl Alcohol 13.75 Disodium EDTA 0.05 Dioctyl Sodium Sulfosuccinate 0.45 Part B Isopropyl Alcohol 11.25 Polyethylene Glycol (M.W. 400) 16.40 Triclosan 0.10 Benzocaine 2.00 Phenol 90% Solution 0.35 100.00 kg The ingredients of Part A are agitated until all solids dissolve. The ingredients of Part B are agitated until a solution results. The mixture of Part B is then blended with the mixture of Part A. The pH of the resulting formulation is 6.5. WHAT WE CLAIM IS:
1. A stable sprayable anesthetic solution comprising: 0.2 - 2.5 percent of a water-insoluble caine-type anesthetic; 0.3 - 0.6 percent of a di-(C5-CR) alkyl sodium sulfosuccinate;
20 - 35 percent of a water-miscible cosmetically acceptable alcohol solvent in which said anesthetic is soluble; 10 - 25 percent of a water-miscible cosmetically acceptable glycol solvent which is a liquid at 25"C and in which said anesthetic is soluble; and at least 50 percent water, wherein the maximum concentration of said solvents is 47 percent.
2. A composition according to claim 1 wherein the concentration of the caine-type anesthetic is 1 to 2 percent.
3. A composition according to claim 1 or 2 in which said caine-type anesthetic is benzocaine.
4. A composition according to any one of claims 1 to 3 wherein the total concentration of the solvents is 35 - 45 percent.
5. A composition according to any one of claims 1 to 4 which, as the alcohol solvent, comprises 20 - 25 percent of isopropyl alcohol and, as the glycol solvent, 15 - 20 percent of polyethylene glycol having a molecular weight of 200 - 600.
6. A composition according to any one of claims 1 to 5 wherein said sulfosuccinate is dioctyl sodium sulfosuccinate.
7. A composition according to claim 6 wherein the dioctyl sodium sulfosuccinate concentration is 0.4 to 0.5 percent.
8. A composition according to any one of claims 1 to 7 in which said water concentration is 50 - 60 percent.
9. A composition according to any one of claims 1 to 8 further comprising 0.2 - 0.5 percent phenol.
10. A topical analgesic product comprising: a non-aerosol spray assembly; and a composition as claimed in any one of claims 1 to 9 within said assembly.
11. An anesthetic composition according to claim 1 and substantially as hereinbefore described.
12. A topical analgesic product according to claim 10 and substantially as hereinbefore defined.
GB2407078A 1977-06-27 1978-05-30 Stable sprayable anesthetic solution Expired GB1574302A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US80996177A 1977-06-27 1977-06-27

Publications (1)

Publication Number Publication Date
GB1574302A true GB1574302A (en) 1980-09-03

Family

ID=25202603

Family Applications (1)

Application Number Title Priority Date Filing Date
GB2407078A Expired GB1574302A (en) 1977-06-27 1978-05-30 Stable sprayable anesthetic solution

Country Status (2)

Country Link
CA (1) CA1099638A (en)
GB (1) GB1574302A (en)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4933362A (en) * 1989-06-06 1990-06-12 Jack Loomstein Sunburn treatment composition
WO2012102936A1 (en) * 2011-01-24 2012-08-02 Quadex Pharmaceuticals Llc Highly penetrating compositions and methods for treating pathogen-induced disordered tissues
US9463180B2 (en) 2013-03-14 2016-10-11 Quadex Pharmaceuticals, Llc Treatment of molluscum contagiosum

Cited By (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4933362A (en) * 1989-06-06 1990-06-12 Jack Loomstein Sunburn treatment composition
WO2012102936A1 (en) * 2011-01-24 2012-08-02 Quadex Pharmaceuticals Llc Highly penetrating compositions and methods for treating pathogen-induced disordered tissues
JP2014503603A (en) * 2011-01-24 2014-02-13 クワデックス・ファーマシューティカルズ・エルエルシー Hyperpermeable compositions and methods for treating pathogen-induced damaged tissue
US8846725B2 (en) 2011-01-24 2014-09-30 Quadex Pharmaceuticals, Llc Highly penetrating compositions and methods for treating pathogen-induced disordered tissues
TWI503133B (en) * 2011-01-24 2015-10-11 Quadex Pharmaceuticals Llc A treatment composition
US9314526B2 (en) 2011-01-24 2016-04-19 Quadex Pharmaceuticals, Llc Highly penetrating compositions with benzocaine for treating disordered tissues
RU2586969C2 (en) * 2011-01-24 2016-06-10 КВАДЕКС ФАРМАСЬЮТИКАЛЗ ЭлЭлСи Compositions with high penetration ability and methods of treating pathogens-induced tissue disorders
AU2012209412B2 (en) * 2011-01-24 2016-09-15 Quadex Pharmaceuticals, Llc Highly penetrating compositions and methods for treating pathogen-induced disordered tissues
US9463180B2 (en) 2013-03-14 2016-10-11 Quadex Pharmaceuticals, Llc Treatment of molluscum contagiosum

Also Published As

Publication number Publication date
CA1099638A (en) 1981-04-21

Similar Documents

Publication Publication Date Title
US4213979A (en) Stable sprayable hydrocortisone product
US5871764A (en) Skin toning formulation
US5397497A (en) Bath additive composition containing polyglycerol fatty acid ester mixture
US4460488A (en) Plant extraction residue as a thickening or opacifying agent for a cosmetic composition
JP2001515022A (en) Use of foamy skin cream, foamy skin protection cream and method for producing the same
DE2234316A1 (en) WATER-FREE AEROSOL FOAM
US4857302A (en) Solubilized benzoyl peroxide and cosmetic solution including solubilized benzoyl peroxide
DE1667237A1 (en) Pressurized preparation and its manufacture
US4285973A (en) Liquid composition for application to the skin
US4925666A (en) Solubilized benzoyl peroxide and cosmetic solution including solubilized benzoyl peroxide
US5688495A (en) Topical deodorant compositions
JPH0299583A (en) New antioxidant system
CA2027218A1 (en) Shaving gel
US3592936A (en) Method of treatment using pharmaceutical composition containing dimethyl sulfoxide
US5294435A (en) Stabilization of emulsion additives to nail polish removers
CZ10295A3 (en) Topic anti-inflammatory preparation based on piroxicam and method of solubilizing piroxicam
IE51097B1 (en) Stable benzoyl peroxide compositions
JPH0840899A (en) Aerosol of oxyconazone nitrate
CA1099638A (en) Stable, sprayable anesthetic solution
JPH02255889A (en) Aerosol composition
JPS61215318A (en) External agent for skin
EP0925783B1 (en) Skin protection preparation
DE2442314C2 (en) Aerosol powder deodorant
US4390442A (en) Non-stinging eye make-up remover composition
US5419896A (en) Hair and body treatment composition

Legal Events

Date Code Title Description
PS Patent sealed
PCNP Patent ceased through non-payment of renewal fee

Effective date: 19950530